Medpace (NASDAQ: MEDP) EVP exercises 12,000 stock options

Rhea-AI Filing Summary

Medpace Holdings, Inc. executive vice president of operations Susan E. Burwig exercised employee stock options for 12,000 shares of common stock at an exercise price of $166.73 per share on March 18, 2026. The option had fully vested on October 27, 2025. Following the transactions, she owns 70,484 shares of common stock and 11,028 derivative securities directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		M		12,000	A	$166.73	70,484	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$166.73	03/18/2026		M			12,000	(1)	10/27/2026	Common Stock	12,000	$0	11,028	D

Explanation of Responses:

1. The option vested in full on October 27, 2025.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Medpace (MEDP) report for Susan E. Burwig?

Medpace reported that executive vice president of operations Susan E. Burwig exercised employee stock options for 12,000 shares of common stock. This derivative exercise converted options into directly owned shares at a preset exercise price disclosed in the filing.

At what price were Susan E. Burwig’s Medpace (MEDP) options exercised?

Susan E. Burwig exercised 12,000 Medpace options at an exercise price of $166.73 per share. This reflects the pre-agreed strike price on the employee stock option grant, not the prevailing market price on the exercise date.

How many Medpace (MEDP) shares does Susan E. Burwig hold after the Form 4?

After the reported transactions, Susan E. Burwig directly holds 70,484 shares of Medpace common stock. She also has 11,028 derivative securities remaining, according to the post-transaction ownership figures in the Form 4 filing.

What type of securities did Susan E. Burwig exercise at Medpace (MEDP)?

She exercised an “Employee Stock Option (Right to Buy)” covering 12,000 underlying shares of Medpace common stock. This transaction is coded “M,” indicating an exercise or conversion of a derivative security rather than an open-market purchase.

When did Susan E. Burwig’s Medpace (MEDP) option vest before exercise?

The employee stock option exercised by Susan E. Burwig vested in full on October 27, 2025. The full vesting meant all 12,000 underlying shares were available for exercise before she completed the transaction on March 18, 2026.

Does the Medpace (MEDP) Form 4 show any share sales by Susan E. Burwig?

The Form 4 shows only the exercise of 12,000 stock options and related acquisition of common shares by Susan E. Burwig. It does not report any open-market sales or dispositions of Medpace common stock in this filing.